Singh Surjit, Sharma Avinash, Jiao Fuyong
Pediatric Allergy Immunology Unit, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Department of Pediatrics, Shaanxi Provincial People's Hospital of Xian, Jiaotong University, Shanghai, China.
Indian J Pediatr. 2016 Feb;83(2):140-5. doi: 10.1007/s12098-015-1890-4. Epub 2015 Sep 24.
Kawasaki disease (KD) is a common vasculitis in children and is the commonest cause of pediatric acquired heart disease in children in Japan and countries in North America and the European Union. It is now being increasingly reported from several developing countries, including China and India. Diagnosis of KD is based on a set of clinical criteria, none of which is individually pathognomonic for this condition. Further, these clinical features appear sequentially over a few days and all findings may not be present at a given point of time. Like many other vasculitides, there is no confirmatory laboratory test for KD. Treatment of KD involves use of intravenous immunoglobulin (IVIg) and aspirin. IVIg is an expensive product and poses several difficulties for patients in developing countries who may find it difficult to access therapy even if a diagnosis of KD has been made in time. In this review, the authors discuss some of these challenges that pediatricians have to face while managing KD in resource constrained settings.
川崎病（KD）是儿童常见的血管炎，在日本、北美和欧盟国家是儿童获得性心脏病最常见的病因。现在包括中国和印度在内的几个发展中国家对其报道也越来越多。KD的诊断基于一系列临床标准，其中没有一项对该病具有单独的诊断特异性。此外，这些临床特征在几天内相继出现，在特定时间点可能并非所有表现都存在。与许多其他血管炎一样，KD没有确诊的实验室检查。KD的治疗包括使用静脉注射免疫球蛋白（IVIg）和阿司匹林。IVIg是一种昂贵的产品，给发展中国家的患者带来了诸多困难，即使及时诊断出KD，他们也可能难以获得治疗。在这篇综述中，作者讨论了儿科医生在资源有限的环境中管理KD时必须面对的一些挑战。
